Volume 2022, Issue 1 9783521
Corrigendum
Open Access

Corrigendum to “Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births”

S. J. Kroese

Corresponding Author

S. J. Kroese

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands umcutrecht.nl

Search for more papers by this author
M. J. H. de Hair

M. J. H. de Hair

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands umcutrecht.nl

Search for more papers by this author
M. Limper

M. Limper

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands umcutrecht.nl

Search for more papers by this author
A. T. Lely

A. T. Lely

Department of Gynecology and Obstetrics, University Medical Center Utrecht, Utrecht, Netherlands umcutrecht.nl

Search for more papers by this author
J. M. van Laar

J. M. van Laar

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands umcutrecht.nl

Search for more papers by this author
R. H. W. M. Derksen

R. H. W. M. Derksen

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands umcutrecht.nl

Search for more papers by this author
R. D. E. Fritsch-Stork

R. D. E. Fritsch-Stork

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands umcutrecht.nl

Medizinische Abteilung Hanusch Krankenhaus and Ludwig Boltzmann Institut für Osteologie, Heinrich-Collin-Straße 30, 1140 Vienna, Austria

Sigmund Freud PrivatUniversität Wien, Vienna, Austria sfu.ac.at

Search for more papers by this author
First published: 09 May 2022

In the article titled “Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births” [1], the authors discovered some discrepancies in the data which were used in the article. Thus, the authors repeated the analyses with the correct data. There was a slightly lower incidence of HELLP (4 in total of which 3 in the non-HCQ group) instead of 6 in total (of which 5 in the non-HCQ group), but statistical significance was similar. Other outcomes were unchanged.

Corrected Table 2 is shown below.

2. Maternal and fetal pregnancy outcome according to HCQ treatment.
Total (N = 110) Non-HCQ (N = 80) HCQ (N = 30) OR (95% CI) $$; p value
Maternal outcome
Preeclampsia  11 (10.9) 9 (11.3) 2 (6.7) 1.0 (1.0-1.0); 0.997
Eclampsia  0 (0) 0 (0) 0 (0)
(i) HELLP  4 (3.6) 3 (3.8) 1 (3.3) 0.93
Prednisone use 63 (57.3) 45 (56.3) 18 (60.0) 0.9 (0.7-1.2); 0.35
Prednisone < 7.5 mg within prednisone users 36 (32.7) 14 (17.5) 22 (73.3) 0.2 (0.0-1.4); 0.10
Fetal outcome
Early spontaneous abortion (<10 weeks of gestation) 19 (17.3) 10 (12.5) 9 (30.0) 1.5 (0.3-9.0); 0.66
Fetal death (>10 weeks of gestation) 3 (2.7) 2 (2.5) 1 (3.3) -
Preterm live birth 18 (16.4) 16 (20.0) 2 (6.7) 0.5 (0.1-2.4); 0.37
 Of which <34 weeks 5 (4.5) 5 (6.3) 0 (0) -
Term live birth 70 (63.6) 52 (65.0) 18 (60.0) 0.9 (0.3-2.7); 0.90
Small for gestational age 15 (13.6) 10 (12.5) 5 (16.7) 2.2 (0.6-7.5); 0.22
β (95% CI)$$; p value
Duration of pregnancy  (median, IQR) 38.9 (37.1-40.0) 38.9 (36.4-40.1) 38.7 (37.7-39.4) -1 (-3.8-1.8); 0.48
Duration of pregnancy in preterm live births# (median, IQR) 35.1 (31.5-36.3) 34.9 (30.9-35.4) 36.8 (36.7-..) 2.4 (1.0-3.8); 0.001
  • Data depicted as numbers (%) unless otherwise indicated. HCQ: hydroxychloroquine; IQR: interquartile range; HELLP: (incomplete) hemolysis, elevated liver enzymes, and low platelet syndrome. $$Dependent variable: pregnancy outcome/prednisone use/duration of pregnancy. Predictor variable: HCQ use (ref = non-HCQ). Adjusted for antiphospholipid status, except for early spontaneous abortion.  Pregnancies ending <10 weeks of gestation were excluded [N = 89/68/21]. Prednisone dose was increased in 4.6% of pregnancies. Of which 5 occurred within one woman. Two were due to elective termination one because of trisomy 21 with Fallot’s tetralogy and one because of infaust prognosis with severe preeclampsia, both occurred within the non-HCQ group. #[N = 18/16/2], duration of pregnancy in weeks.

Additionally, the email address of the corresponding author should be changed to “[email protected].”

The authors confirm that this does not affect the results and conclusions of the article, and the editorial board agrees to the publication of a corrigendum.

    The full text of this article hosted at iucr.org is unavailable due to technical difficulties.